Evaluation of Efficacy and Safety of Somatostatin Used as Inflow Modulator in Liver Transplantation.
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
This study is a 5 day, single-center, randomized, double blind, placebo-controlled study to
evaluate the efficacy and safety of Somatostatin used as inflow modulator in liver
transplantation. Patient systemic and hepatic dynamics will be collected and recorded at
predefined time-points. To evaluate the ischemia-reperfusion injury, it is planned to perform
liver biopsies at two different time-points to compare the liver structure and proteomic
variations.